This is kind of a big deal. Over the last couple decades there have been fewer and fewer antibiotics researched and approved by the FDA. Vox has a nifty chart that shows the decline of new approval over the last 30 years. With the rise of drug resistant bacteria, this is indeed a problem. Hopefully there are more antibiotics like this one in the pipeline.
Here are Phil Gingrey and Gene Greene’s thoughts.
Gingrey and Greene applaud FDA approval of first GAIN Act antibiotic
The U.S. Food and Drug Administration (FDA) recently approved the first antibacterial medication aimed at stopping the rapid spread of antibiotic-resistant “Superbugs,” which were previously impervious to available treatments. The new drug, Dalvance (dalbavancin), is the first Qualified Infectious Disease Product (QIDP) to be approved for human consumption under Reps. Phil Gingrey, M.D., and Gene Greene’s Generating Antibiotic Incentives Now Act – a bipartisan effort to defeat the threat of these drug-resistant infections.
Rep. Gingrey: “The GAIN Act has been a great success for the medical community and their patients. The approval of Dalvance is a momentous step in mitigating the risk antibiotic-resistant bacteria poses to patients, and will spur greater investment in future treatments to help fight this ever-increasing public health threat.”
Rep. Greene: “For too long, new drugs have been scarce, while resistant bacteria have become rampant. GAIN was a critical first step in addressing the need for newer and more effective antibiotics and this approval marks the first success of the law. As we celebrate this achievement, we must not abandon our commitment to addressing the anemic antibiotic pipeline and barriers to research, development and innovation of new and better antimicrobials to treat the increasing number of drug-resistant infections.”